PHASE II TRIAL OF FOLFIRI REGIMEN PLUS BEVACIZUMAB ALTERNATED WITH OXALIPLATIN-BASED HEPATIC ARTERIAL INFUSION PLUS DE GRAMONT REGIMEN AND BEVACIZUMAB IN THE TREATMENT OF UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER

ABSTRACT: Primary objectives: TUMOR RESPONSE RATE (RR)

DISEASE(S): Unresectable Liver Metastases From Colorectal Cancer

PROVIDER: 2522576 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR